Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes [Financial Post (Toronto, Ontario, Canada)]
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
Achieve Life Sciences, Inc. (NASDAQ: ACHV) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $18.00 to $11.00. They now have an "outperform" rating on the stock.
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2024 Earnings Call Transcript [Yahoo! Finance]